New Drug Increases Lung Cancer Patients Survival

POSTED: Wednesday, March 25, 2009 - 8:16am

UPDATED: Thursday, February 25, 2010 - 11:32am

In medical news, authorities in Cuba say the first vaccine to extend lives of lung cancer patients has been approved for use.

The drug is called Cimavax EGF and has been shown to increase survival rates on average by four to five months, and much longer in some patients. Experts say Cimavax EGF has few side effects because it's a modified protein attacks only cancer cells. The cost for the treatment has not yet been determined and the drug has only been approved for clinical trials in the U.S. and the approval would most likely be in the future.

Comments News Comments

Post new Comment